Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

Objective Autophagy participates in the progression of hepatocellular carcinoma (HCC) and the resistance of HCC cells to sorafenib. We investigated the feasibility of sensitising HCC cells to ...

经过DataTwin图像查重流程，发现李春晓、江萍、王俊杰团队等人近期在某权威期刊上发表的"Sorafenib enhanced the function of myeloid-derived suppressor cells in ...

编者按：在近期召开的巴黎2025 EASL肝癌峰会上，由全球肝癌领域权威专家、美国纪念斯隆-凯特琳癌症中心Ghassan ...

The panelist discusses first-line options including atezolizumab plus bevacizumab, lenvatinib, and sorafenib. Second-line treatments include regorafenib, cabozantinib, and ramucirumab. Clinical trials ...

That takes CTLA4 inhibition into uncharted territory in HCC, as BMS' Yervoy plus Opdivo is FDA-approved only as a second-line treatment after sorafenib, sold by Bayer as Nexavar and also available ...

Feb. 20, 2025 — Biologists have discovered a new type of RNA-splicing regulation that helps to determine which protein-coding exons will be included in messenger RNA ...

为解决肝细胞癌（HCC）预后差、缺乏有效生物标志物的问题，研究人员开展了 RECQL4 在 HCC 中作用的研究，发现其可预测预后、影响药物敏感性，对 HCC 治疗意义重大。 肝细胞癌（Hepatocellular carcinoma，HCC），这个隐匿在人体肝脏内的 “健康杀手”，一直以来都是全球癌症领域的一大难题。它不仅是全球第六大常见癌症，更是癌症相关死亡的第三大主因。多数 HCC ...

The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...

Several factors can affect thyroid test results, the blood tests used to measure thyroid-stimulating hormone (TSH), triiodothyronine (T3) and thyroxine (T4), and the levels that are key to your ...